Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9301982rdf:typepubmed:Citationlld:pubmed
pubmed-article:9301982lifeskim:mentionsumls-concept:C0162791lld:lifeskim
pubmed-article:9301982lifeskim:mentionsumls-concept:C1334631lld:lifeskim
pubmed-article:9301982lifeskim:mentionsumls-concept:C0282563lld:lifeskim
pubmed-article:9301982lifeskim:mentionsumls-concept:C1697858lld:lifeskim
pubmed-article:9301982lifeskim:mentionsumls-concept:C2826567lld:lifeskim
pubmed-article:9301982pubmed:issue2lld:pubmed
pubmed-article:9301982pubmed:dateCreated1997-10-30lld:pubmed
pubmed-article:9301982pubmed:abstractTextThe in-vitro activity of azithromycin, clarithromycin, erythromycin, josamycin, midekamycin, roxithromycin and clindamycin against 674 Gram-negative and Gram-positive clinical isolates, including methicillin-resistant Staphylococcus aureus, was determined by agar dilution, microdilution and agar diffusion with Mueller-Hinton medium according to the Deutsches Institut für Normung (DIN) 58940 guidelines. The results obtained by regression analysis and the error-rate-bounded method of Metzler-DeHaan indicate that common interpretative criteria (breakpoints) for test discs may be assigned to susceptible/resistant Gram-positive strains for all antibiotics tested. The following tentative DIN values are suggested for 15 microg macrolide discs: for susceptible Gram-positive and Gram-negative strains, an inhibition zone diameter (IZD) of > or = 26 mm at a corresponding MIC of < or = 2 mg/L; for resistant Gram-positive strains, an IZD of < or = 21 mm; for resistant Gram-negative strains, an IZD of < or = 19 mm at a corresponding MIC of > or = 8 mg/L. For Haemophilus influenzae only, breakpoints for azithromycin are suggested with IZDs of > or = 21 mm for susceptible and < or = 18 mm for resistant.lld:pubmed
pubmed-article:9301982pubmed:languageenglld:pubmed
pubmed-article:9301982pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9301982pubmed:citationSubsetIMlld:pubmed
pubmed-article:9301982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9301982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9301982pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9301982pubmed:statusMEDLINElld:pubmed
pubmed-article:9301982pubmed:monthAuglld:pubmed
pubmed-article:9301982pubmed:issn0305-7453lld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:WildfeuerAAlld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:SchmalreckA...lld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:SchlenkRRlld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:VanceAAlld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:ReiserAAlld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:KottmannIIlld:pubmed
pubmed-article:9301982pubmed:authorpubmed-author:RufferUUlld:pubmed
pubmed-article:9301982pubmed:issnTypePrintlld:pubmed
pubmed-article:9301982pubmed:volume40lld:pubmed
pubmed-article:9301982pubmed:ownerNLMlld:pubmed
pubmed-article:9301982pubmed:authorsCompleteYlld:pubmed
pubmed-article:9301982pubmed:pagination179-87lld:pubmed
pubmed-article:9301982pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:meshHeadingpubmed-meshheading:9301982-...lld:pubmed
pubmed-article:9301982pubmed:year1997lld:pubmed
pubmed-article:9301982pubmed:articleTitleSusceptibility testing of macrolide and lincosamide antibiotics according to DIN guidelines. Deutsches Institut für Normung.lld:pubmed
pubmed-article:9301982pubmed:affiliationMicrobiology Laboratories Research & Development, Pfizer/Mack, H. Mack Nachf., Illertissen, Germany.lld:pubmed
pubmed-article:9301982pubmed:publicationTypeJournal Articlelld:pubmed